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Epstein–Barr virus (EBV) is a human gammaherpesvirus, which infects most of 
the human population worldwide, and is one of the first human viruses found to be 
associated with cancer. EBV has a latent lifecycle characterized by limited gene 
expression, and a lytic lifecycle where infectious virions are produced. Latent infection is 
responsible for causing various types of cancers, and inducing the EBV lytic cycle has 
been suggested as a new approach for treating these types of malignancies. The unfolded 
protein response (UPR) is one of the major pathways which leads EBV to enter the lytic 
replication cycle. Thus several UPR inducers such as bortezomib are widely used for 
activating EBV in various cancer cell lines in laboratory.  Recent investigations have 
demonstrated that clofoctol, an antibiotic drug that has anti-proliferative activities in 
prostate cancer cell lines, activates the UPR. In order to investigate whether clofoctol 
activates the UPR and leads to the viral activation, we tested the drug on various types of 
EBV-positive cancer cell lines, including the BX1-Akata Burkitt lymphoma cell line, 
lymphoblastoid cell line (LCL), SNU719 gastric cancer cell line and C666 
nasopharyngeal cancer cell line.   
Here, we show that clofoctol induces EBV lytic activation in a variety of cancer 
cell lines at a clinically achievable concentration. The effect was similar to that seen with 
bortezomib, but was more rapid and worked in broader range of the cell lines. Viral 
immediate early lytic gene Zta, early lytic gene Bmrf1 and late lytic gene gp350 
expression were increased in RNA level. Increased Zta protein and EBV DNA copy 
number were confirmed in BX1-Akata cells. However, the expression of late protein 
gp350 was not detected after clofoctol treatment. A Raji infection assay using EBV 
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expressing GFP showed that clofoctol treatment does not lead to infectious virion 
production.   
Similar to a previous report with prostate cancer cell lines, clofoctol induces all 
three pathways of UPR – PERK, IRE1 and ATF6. Activation of the PERK branch was 
confirmed by demonstration of increased eIF2α phosphorylation, and increased ATF4 
and CHOP expression. Activation of IRE1 and ATF6 pathways was demonstrated by an 
increase in XBP1 spliced RNA and Bip RNA, respectively. With modulation of the 
PERK branch by shRNA-mediated knockdown and a PERK-specific inhibitor, we found 
that the PERK pathway mediates EBV lytic activation by clofoctol as inhibited PERK led 
to reduced Zta expression. Activated PERK leads to eIF2α phosphorylation which in turn 
inhibits most translation, but allows some RNAs including ATF4 to be translated. In our 
results, Zta protein synthesis was enhanced with PERK activation and eIF2α 
phosphorylation by clofoctol treatment, suggesting Zta translation overcomes the block to 
translation mediated by eIF2α phosphorylation. Furthermore, we found the PERK 
pathway differentially regulates viral lytic gene expression at the protein level. Clofoctol 
treatment alone triggers expression of the immediate early protein Zta. However, ZTA 
expression was reduced by treatment with a PERK inhibitor. In contrast, expression of 
the viral late lytic protein gp350 was not increased by clofoctol alone but was increased 
by the combination of clofoctol and PERK inhibitor.  This result suggests that clofoctol 
activates other branches of the UPR and that these also are important in driving EBV 
lytic infection. 
eIF2α phosphorylation by PERK is also a part of the integrated stress response 
(ISR) and there are more kinases that induce the phosphorylation of eIF2α, including 
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HRI, PKR, and GCN2. In order to demonstrate that activation of all eIF2α kinases results 
in EBV lytic induction, we performed pharmacologic inductions of four kinases and 
evaluated the effect on virus in BX1-Akata cells. The specific activation of each of the 
eIF2α kinases triggered EBV Zta RNA expression and increased GFP expression in BX1-
Akata cells.   
Our results show that clofoctol activates EBV lytic gene expression, and that this 
expression is partially mediated by the PERK pathway of UPR and ISR. Inhibition of 
global protein translation by the PERK pathway allows immediate early Zta protein 
synthesis but blocks late protein gp350 synthesis and virion production. We also found 
that other ISR stimuli can lead to viral lytic induction. These results suggest the 
possibility of new approaches to modulate viral gene expression for therapeutic purposes 
as well as providing new insights into physiologic stimuli that may trigger EBV 
reactivation in vivo.   
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Epstein–Barr virus (EBV) is a virus of the gamma-herpes virus family and is also 
called human herpesvirus 4 (HHV-4).  The double stranded DNA genome consists of 
172kb and encodes more than 80 gene products [1]. The viral genome is surrounded by a 
nucleocapsid and viral envelope, which forms a viral particle. EBV infects mostly B cells 
and epithelial cells [2] and the initial Infection with EBV is thought to occur by contact 
with oral secretions [3]. Approximately 90% of the human population is infected with 
EBV. Infection with EBV usually occurs at early ages without symptoms and persists 
within the body in resting memory B cells as a latent infection [4]. Viral infection in 
adolescents and adults frequently results in infectious mononucleosis [5]. EBV is also 
associated with various types of cancers including nasopharyngeal carcinoma [6], Burkitt 
lymphoma [7] and Hodgkin lymphoma [8].  Patients with severe combined 
immunodeficiency, recipients of transplants, and patients with the acquired 
immunodeficiency syndrome (AIDS) have high incidence of EBV-associated 
lymphoproliferative disease, since their impaired T-cell immunity is incapable of 




EBV infection in B cells in vitro induces cell proliferation and can generate 
immortalized B cell lines called Epstein-Barr virus-transformed lymphoblastoid cell lines 
(LCL) [2]. Once the virus infects cells, EBV exists in two states - lytic and latent [11]. 
Unlike in lytic state where viral replication is followed by infectious virion production, 
the virus mostly exists in a latent state with restricted viral gene expression. There are 9 
latent viral proteins in total. During the latency period, the viral genome circularizes and 
is maintained as an extrachromosomal episome and expression of viral protein EBNA1 is 
enough to replicate the episome by tethering it to the host chromosome, thus enabling 
episomal replication by cellular enzymes in dividing cells [12, 13]. EBNA2 is a main 
contributor for EBV driven cell growth by transcriptionally regulating viral and host 
protein expression. EBNA2 has been shown to bind CBF1/RBPJk and mimics the notch 
intracellular domain in the notch signaling pathway [14, 15]. LMP1 and LMP2A are the 
key latent membrane proteins that act as constitutively active receptors, which drive the 
signaling pathway in a ligand-independent manner [16, 17]. LMP1 is a functional 
homolog to CD40 [18] and LMP2A mimics B cell receptor signaling which is essential 
for the B cell survival [17].  Depending on cell type and differentiation stage of the B cell, 
EBV latency patterns can be categorized into three types of latency programs. The virus 
only expresses EBNA1 and some EBERs in latency 1, and with additional LMP1 and 
LMP2A expression, it becomes latency 2 which is typically shown in epithelial cells. All 
EBV latent genes are expressed during latency 3 and EBV- immortalized lymphoblastoid 




Lytic infection  
The viral lytic phase is when virus replication occurs and the entire lytic gene 
repertoire is expressed producing infectious viral particles. This is rarely detected in 
immunocompetent humans as a result of being eliminated immediately by the cytotoxic 
immune response [20]. However, in the case of immunosuppressed patients, an 
abnormally increased level of infectious viral particles found in plasma can cause cell-to-
cell transmission, resulting in a high incidence of EBV-induced lymphoproliferative 
disorders (LPD) [21]. Unlike the latent genes, lytic genes are expressed in a temporally 
regulated manner. The first gene that appears is the viral immediate early gene BZLF1, 
which encodes for Zta (or Z) protein that acts as a transcription factor regulating delayed 
early lytic gene expression to enable the viral DNA replication. Following this is viral 
late gene expression, which mostly encodes viral structural proteins in order to generate 




The switch from latent infection to lytic infection is called EBV reactivation [22]. 
Although the precise mechanism of viral reactivation from the latent state in vivo is not 
completely known, lytic infection in cell culture systems has widely been investigated. 
After the first discovery of Z (Zta, or BZLF1) initiating viral lytic infection in latently 
infected cell lines [23, 24], there has been extensive investigations of the cellular 
regulation of the Z promoter and many chemical agents to induce lytic infection have 
been revealed and developed. For example, cross-linking the B-cell receptor with anti-
immunoglobulin was used to induce lytic cycle in Akata cell lines [25] and other 
chemical agents such as phorbol esters, TPA [26], and calcium ionophores [27] were all 
shown to activate Z transcription by their effects on specific cellular pathways. 
The Z promoter has two types of cis acting motifs – ZI and ZII, which are 
important for activating the promoter in response to various lytic inducing stimuli [28]. 
The ZI motif plays a dual role as a negative regulator and positive regulator of Z 
promoter activity. In the absence of lytic inducing stimuli, the ZI motif binds to a cellular 
protein MEF2D that represses Z transcription [29]. However, virus lytic inducing agents 
such as phorbol esters and anti-IgG prevent this interaction and convert it to a positive 
regulator for activating the promoter [30, 31]. 
The ZII motif is a CREB-responsive element (CRE) and is the other essential part 
for Z transcription [32]. Various cellular transcription factors such as c-jun/c-fos (AP1) 
[33, 34], CCAAT/enhancer-binding proteins (C/EBP) [35], and a spliced form of X-box-
binding protein 1 (XBP1s) [36, 37] were found to act on the ZII motif to enhance the Z 
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transcription. The activation of transcription factors which bind to the ZII motif are 
typically mediated by the phosphorylation of cellular kinases such as c-jun N-terminal 
kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) [34]. Once Z is 
activated by the cellular factors, the Z product is able to autoactivate itself by binding to 
another ZIII motif (ZRE site) and expression of Zta protein is enough to switch from 
latent to lytic cycle [38-40]. The initial expression of Z drives the expression of the other 
viral intermediate early (IE) gene, BRLF1 [41, 42] and both work together to activate 




EBV associated cancers 
EBV is well known as the causative virus for several cancers such as Burkitt 
lymphoma, post-transplant lymphoproliferative disorder (PTLD) and nasopharyngeal 
carcinoma (NPC).  
Burkitt lymphoma is where the virus was first discovered in tumor cells [2]. EBV 
is thought to have a causal role in African Burkitt lymphoma as EBV is found in most 
cases and the majority of tumor cells harbor the viral genome [2]. Burkitt lymphoma is 
characterized by a chromosomal translocation of the c-myc oncogene near the 
immunoglobulin region, which drives upregulation of c-myc gene expression [46]. 
Overexpression of c-myc was shown to increase tumorigenicity in EBV-transformed 
lymphoblastoid cell lines.(LCL) [47]. 
Post-transplant lymphoproliferative disorder (PTLD) is another type of cancer 
highly associated with EBV [21]. This occurs after solid organ or bone marrow 
transplantation and approximately 50–80% of PTLD biopsies are positive for EBV within 
the tumor cells [48]. It is suspected that a weakened immune system allows EBV to 
proliferate the malignant cells.  
There are also epithelial cancers associated with EBV, such as nasopharyngeal 
carcinoma (NPC). NPC is mostly found in southern China and is among the most 
common cancers in the area, where the incidence is about 50 per 100,000 persons every 
year [6]. It is thought that EBV infection in single cell initiates the development of tumor 
growth as clonal EBV DNA is found in preinvasive lesions of the nasopharynx [49]. 
EBV genome and proteins are also found in certain types of gastric carcinomas such as 
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undifferentiated lymphoepithelioma-like carcinomas and is thought to have a pathogenic 
role in those tumors [50]. 
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EBV targeted therapy 
The presence of the EBV genome in tumors offers a potential advantage as it 
serves as a tumor-specific target. The strategies for EBV-targeted therapies have been 
implemented for various types of EBV-associated cancers.  One of these strategies is 
using an anti-viral nucleoside analog prodrug, ganciclovir, which is selectively 
phosphorylated by viral kinases to become the active cytotoxic form. In this case, viral 
lytic induction to enhance viral kinase expression would target EBV-harboring cells 
exclusively.  Epigenetic modulators and some anti-cancer chemotherapy drugs were 
shown to induce lytic activation and have a killing effect with ganciclovir in various 
types of EBV cancer cell lines [51-53] as well as in a clinical trial [54]. However, the 
evidence suggesting that tumor killing in these cell lines or in this clinical trial is truly 
EBV-specific remains largely conjectural. Further research revealed several other cellular 
mechanisms that result in Zta induction including ER stress and the ATM/p53 pathway 
during genotoxic stress response [55, 56] and clinical drugs that elicit the pathways were 
proven to have an effect on EBV lytic gene expression and a cytotoxic effect together 
with antiviral nucleoside analogs in vitro and in vivo [57, 58].  
EBV-specific cytotoxic T lymphocytes (EBV CTL) therapy was developed for 
immunocompromised patients where a suppressed T cell response to EBV infected cells 
is thought to drive tumor development [59]. These types of tumors, such as post-
transplant-lymphomas, typically show a type III latency pattern which expresses the full 
spectrum of latent viral genes and are most readily targeted. Viral lytic genes are also 
readily targeted by normal host T cell responses.  
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CHAPTER 1: CLOFOCTOL INDUCES EBV LYTIC ACTIVATION IN 
MULTIPLE CELL LINES 
SUMMARY 
Epstein-Barr virus (EBV) is a human gammaherpesvirus which is responsible for 
causing various types of cancer. The unfolded protein response (UPR) is one of the major 
pathways which leads EBV to enter the lytic replication cycle. Thus several UPR 
inducers such as bortezomib are widely used for activating EBV in various cancer cell 
lines in laboratory [60]. Recent investigations have demonstrated that an antibacterial 
drug, clofoctol, which has anti-proliferative activities in prostate cancer cell lines, 
activates the UPR [64]. As it was previously reported that bortezomib induces EBV lytic 
gene expression through the UPR pathway, we investigated whether clofoctol had an 
effect on the activation of EBV in latently infected cancer cell lines. Here, we show that 
clofoctol leads to EBV activation in lymphoma cell lines, epithelial cancer cell lines and 
lymphoblastoid cell lines. Thus clofoctol activates a broader range of EBV cell lines than 
does bortezomib. Increased EBV genome copy number per cell resulting from clofoctol 
treatment was demonstrated by qPCR. Clofoctol also increased viral immediate early 
lytic gene Zta, early lytic gene Bmrf1, and late lytic gene gp350 RNA expression as 
demonstrated by qRT-PCR. In the BX1-Akata Burkitt lymphoma cell line, increased viral 
DNA copy number (as measured by marker GFP expression) and increased Zta protein 
expression was shown by immunofluorescence and immunoblot. In contrast, clofoctol 
treatment did not increase gp350 protein expression, a late viral protein. Furthermore, in a 
Raji infection assay that utilizes GFP-marked EBV, it was clear that clofoctol treatment 




Epstein–Barr virus (EBV), a human gammaherpesvirus, is a cancer-associated 
virus and it is mostly in the latent state in cancer cells. Physiological stimuli that induce 
the lytic cycle in vivo are yet not clear but some reagents have been known to trigger viral 
reactivation in vitro. There has been growing interest in pharmacologic activation of lytic 
viral gene expression in EBV (+) tumor tissue and several recent therapeutic strategies 
require activation of viral gene expression to achieve tumor regression [61]. One of 
reagents studied for the lytic induction strategy is bortezomib, a clinically approved 
proteasome inhibitor used for multiple myeloma treatment. A previous report showed that 
bortezomib induces EBV lytic replication by inducing the unfolded protein response 
(UPR) in vitro [60] and the effect was also studied in an in vivo tumor model system [57]. 
In a recent study, the antibiotic drug clofoctol has been shown to inhibit the 
growth of prostate cancer cells at clinically achievable concentrations [62, 63], which was 
mediated by activation of UPR pathways [64]. Clofoctol ([2-(2,4-dichlorobenzyl)-4-
(tetramethyl-1,1,3,3-butyl)phenol]) is a synthetic antibacterial drug which is effective on 
various gram-positive and gram-negative bacteria.  This drug has been widely used in 
France and Italy for treating mild upper respiratory tract infections and is well-tolerated 
in patients [65, 66]. While the exact mechanism of action is not completely understood, it 
has been suggested to act on the cytoplasmic membrane of bacteria and inhibit cell wall 
synthesis [67]. Based on previous evidence showing that EBV Zta expression can be 
activated by pharmacologic activation of UPR pathways, we sought to examine the effect 
of clofoctol on EBV lytic activation. 
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There are several types of cancer cell lines that harbor EBV. The Akata cell line 
was derived from a Burkitt lymphoma patient and the BX1-Akata cell line is an 
engineered derivative cell line that carries recombinant EBV expressing GFP [68, 69]. 
Treatment with lytic inducing agents such as anti-immunoglobulin drive the viral lytic 
cycle, which can be visualized by enhanced GFP expression.  C666 is a nasopharyngeal 
carcinoma cell line [70] and SNU719 is a gastric carcinoma cell line, both of which are 
derived from tumors naturally infected with EBV [71].  A lymphoblastoid cell line (LCL) 
is a B cell line that was immortalized by EBV in vitro. All of the above cell lines are 
predominantly latently infected and responses to lytic inducers vary among the cell types 
[72].  
Lytic induction can be monitored by several types of laboratory techniques. 
Quantitative polymerase chain reaction (qPCR) analysis is used to measure the copy 
number of EBV genomes. A convenient EBV standard is DNA from the Namalwa 
Burkitt lymphoma cell line that has 2 copies of integrated EBV genome per cell [73]. 
EBV lytic RNA expression can also be measured by quantitative reverse transcribed 
polymerase chain reaction (qRT-PCR). EBV lytic proteins can be measured using 
immunoblot or immunofluorescence. The first lytic gene expressed is the EBV immediate 
early lytic gene BZLF1 which encodes for Zta. This induces the other immediate early 
lytic gene BRLF1 expression and both drive the serial expression of early lytic genes. 
The majority of viral early lytic genes encode enzymes and proteins that work for 
efficient viral DNA replication, such as the viral DNA polymerase processivity factor, 
Bmrf1 gene. Viral genome replication is followed by viral late gene expression, which 
encodes viral structural proteins, such as gp350 encoding for the viral membrane 
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glycoprotein. Finally the replicated viral DNA genome is incorporated into the viral 
capsid structure and the nucleocapsids are enveloped with the tegument proteins and 
glycoprotein-rich membrane, which results in viral particle formation [74]. 
By using various laboratory techniques, we investigated the effects of clofoctol on 




MATERIALS AND METHODS  
Cell Culture.  Akata and Raji are EBV (+) Burkitt lymphoma cell lines. BX1-
Akata, an engineered derivative Akata line which carries a recombinant EBV that 
constitutively expresses a green fluorescent protein (GFP), was a gift from L. Hutt-
Fletcher (Louisiana State University). SNU-719, a naturally derived EBV (+) gastric 
cancer cell line, was a gift from J. M. Lee (Yonsei University). C666-1 is an EBV (+) 
nasopharyngeal carcinoma cell line and LCL is an EBV-immortalized lymphoblastoid 
cell line. All cell lines were cultured in RPMI 1640, 2 mM L-glutamine, 100 IU/mL 
penicillin, 100 μg/mL streptomycin and 10% v/v fetal bovine serum (FBS). 500 μg/mL 
G418 (geneticin; Life Science Technologies) was added to the culture medium for the 
BX1-Akata cell line. 
 Reagents.  Clofoctol was a gift from J. Liu (Johns Hopkins University School of 
Medicine) and purchased from Sigma-Aldrich. Bortezomib (20 nM) was from 
Millennium Pharmaceuticals, tunicamycin (2 μg/mL) was from Enzo Life Sciences, anti-
IgG (10 μg/mL) was from Sigma-Aldrich. 
 qPCR.  DNA was extracted from cells using a QIAamp DNA mini kit (QIAGEN). 
Real-time PCR was performed with EBV BamH-W primers and the BamH-W 
fluorescent probe. BamH-W Forward (5’-CCCAACACTCCACCACACC-3’), BamH-W 
Reverse (5’-TCTTAGGAGCTGTCCGAGGG-3’) and the BamH-W fluorescent probe 
(5’-(FAM)CACACACTACACACACCCACCCGTCTC(BH1)-3’) were used. EBV copy 
numbers were normalized compared to serially diluted Namalwa cell DNA. Each reaction 
was 20 μL in total, including 2 μL DNA at 50 ng/mL, 2 EBV primers at 500 nM, the 
14 
 
probe at 200 nM and SsoAdvance Supermix (Bio-Rad). DNA was amplified at 95°C for 
2 minutes for 1 cycle and 95°C for 5 seconds and 60°C for 10 seconds, for total 40 cycles 
in a CFX96 real time thermocycler (Bio-Rad).  
 qRT-PCR.  RNA was extracted using an RNeasy Mini Kit (QIAGEN) and 
reverse-transcribed into cDNA by using iScript reverse synthase kit (Bio-Rad). Reverse 
transcription was performed using a CFX96 real time thermocycler (Bio-Rad). SsoFast 
Evagreen Supermix (Bio-Rad) with 500 nM primers and cDNA corresponding to 25 ng 
of the RNA was used for each reaction. cDNA was amplified at 95°C for 30 seconds for 
1 cycle and 95°C for 5 seconds and 60°C for 10 seconds, for a total of 40 cycles in a 
CFX96 real time thermocycler. EBV Zta primers used were Forward (5’-
ACATCTGCTTCAACAGGAGG-3’) and EBV Zta Reverse (5’-
AGCAGACATTGGTGTTCCAC-3’). EBV Bmrf1 primers used were Forward (5’-
CTAGCCGTCCTGTCCAAGTGC-3’) and EBV Bmrf1 Reverse (5’-
AGCCAAACGCTCCTTGCCCA-3’). EBV gp350 primers used were Forward (5’-
GTCAGTACACCATCCAGAGCC-3’) and EBV gp350 Reverse (5’-
TTGGTAGACAGCCTTCGTATG-3’).  GAPDH primers were used as a control for 
normalization. GAPDH primers used were Forward (5’-
TCTTTTGCGTCGCCAGCCGA-3’) and GAPDH Reverse (5’-
AGTTAAAAGCAGCCCTGGTGACCA-3’). 
 Immunoblots.  For protein extractions, 1.5 x 107 cells were washed in PBS and 
the pellets were resuspended in a buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 
100 μM EDTA and 1X protease/phosphatase inhibitor cocktail (Cell Signaling 
Technologies). After 15 minutes incubation in ice, 0.6% NP-40 was added and vortexed 
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for cell lysis. The cytosolic proteins were separated by centrifugation at 10,000 rpm for 
30 seconds and collected by removing the supernatant. The pellet containing the nuclear 
proteins was resuspended in a buffer containing 20 mM HEPES (pH 7.9), 400 mM NaCl, 
1 mM EDTA and 1X protease/phosphatase inhibitor cocktail (Cell Signaling 
Technologies).  After 15 minutes of rotation at 4°C, the nuclear proteins were isolated by 
centrifugation at 13,000 rpm at 4°C for 5 minutes and collected by removing the 
supernatant. SDS-PAGE and Western blotting were performed with equal amounts of 
proteins per sample and ECL chemiluminescent detection reagents (GE Healthcare) were 
used in conjunction with autoradiography film (Denville Scientific) detection. Antibody 
against EBV Zta was from Santa Cruz Biotechnology and anti- β actin was from Sigma-
Aldrich. 
 Immunofluorescence. 1.5 x 105 cells were spun onto microscope slides by using a 
Cytospin centrifuge, fixed and permeabilized with ice-cold methanol for 15 minutes, 
blocked in PBS with 5% Bovine serum albumin (BSA) for 30 minutes, incubated with 
anti-EBV Zta or gp350 mouse antibody (Santa Cruz Biotechnology) at 1:50 for 1 hour, 
washed three times for ten minutes each with 5% BSA, 0.1% Tween-20 in PBS and Cy3 
goat anti-mouse antibody (Jackson Immunoresearch) was applied to the cells for 1 hour 
at room temperature. After 3 final washes, the cells were stained with Vectashield 
mounting media with DAPI (Vector Laboratories). A ZOE Fluorescent cell imager (Bio-
Rad) was used for cell fluorescence detection. 
 Raji infection assay. BX1-Akata cells were treated with anti-immunoglobulin G 
(MilliporeSigma, 10 μg/ml), TPA (20 ng/ml)/NaB (3 mM) or clofoctol (20 uM) and 
incubated for 4 days. After spinning the cells, the supernatant was passed through a 
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Millex-HV Syringe Filter Unit (0.45 μm, MilliporeSigma) and concentrated with a 
centrifugal filter (Amicon Ultra-15 Centrifugal Filter Unit, MilliporeSigma). Raji cells 
were infected with the concentrated cell free virus and TPA/NaB were added 24 hours 
after the infection. The GFP positive cells were counted 24 hours after TPA/NaB 




We previously reported that bortezomib induces EBV lytic gene expression 
through the UPR pathway. In this vein, we investigated whether clofoctol can induce the 
activation of EBV in latently-infected lymphoma cell lines. As shown in Figure 1-1, 
treatment of clofoctol increased the expression of EBV immediate early gene Zta RNA in 
BX1-Akata, Akata EBV (+) and Raji cells and an increased Zta protein level was also 
found by immunoblot. We also confirmed that further rounds of viral lytic gene 
expression were upregulated by clofoctol, as assessed by qRT-PCR for the early lytic 
gene Bmrf1 and the late EBV envelope glycoprotein gene gp350 (Fig. 1-2). The 
increased level was similar to that seen with bortezomib. We also observed a dose-
dependent increase of EBV viral DNA level in BX1-Akata cells with clofoctol treatment 
(Fig. 1-3). Green fluorescent protein (GFP) expression in the BX1-Akata cell line serves 
as an indicator of EBV lytic replication, and anti-IgG treatment results in an increase of 
GFP expression. The number of GFP (+) cells in the BX1-Akata cell line was increased 
with clofoctol treatment as shown in Figure 1-3b. We further confirmed the increased Zta 
protein expression by performing an immunofluorescence assay. However, clofoctol 
treatment did not increase late lytic gene gp350 protein expression (Fig. 1-4). 
EBV is also associated with epithelial cell cancers such as gastric carcinoma and 
nasopharyngeal carcinoma (NPC). Thus we tested the effects of clofoctol on EBV in 
C666, a native EBV (+) NPC cell line and in SNU-719, a native EBV (+) gastric 
carcinoma cell line. Like EBV-harboring lymphoma cells, the EBV DNA level as well as 
Zta RNA level were all increased by clofoctol treatment in C666 and SNU-719 cells (Fig. 
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1-5). Based on these results, we conclude that clofoctol induces EBV lytic gene 
expression in naturally infected EBV (+) epithelial cancer cell lines. 
Although bortezomib is a potent EBV lytic inducer, it has limited effects on lytic 
activation in EBV-immortalized lymphoblastoid cells (LCLs). We tested clofoctol in 
LCLs to see whether latently infected EBV in LCLs can be reactivated by clofoctol 
treatment.  As shown in Figure 1-6, we found a strong effect in activating virus in LCLs, 
which was measured by increased expression of EBV Zta, Bmrf1 and gp350 RNA. 
Clofoctol treatment increased the number of Zta protein expressing cells in a similar level 
to the RNA increase. These results indicate that clofoctol induces EBV lytic activation in 
LCLs and is likely to have a distinct mechanism for this induction.  
We further investigated whether EBV lytic gene expression and lytic replication 
induced by clofoctol lead to enhanced infectious virion production. The virus producer 
BX1-Akata cell line was treated with clofoctol as shown in Figure 1-7a, and the cell-free 
BX1 virus supernatants were used to perform a Raji cell infection assay. We found that 
no GFP (+) Raji cells were detected in samples with clofoctol-induced BX1 virus, which 











Figure 1-1. Clofoctol activates EBV Zta expression in lymphoma cell lines 
A. BX1-Akata, Akata EBV(+) and Raji cells were treated with clofoctol 20 uM for 24 
hours and isolated RNA were used to perform qRT-PCR for detecting Zta RNA levels. 
B. Expressions of Zta proteins were measured by western blot at indicated time points 24 
hours after the treatment in BX1-Akata and Akata EBV(+) cells.                        
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Figure 1-2. Clofoctol activates EBV lytic gene expression in BX1-Akata cells 
BX1-Akata cells were treated with tunicamycin (TM, 2 μg/mL), clofoctol (CLF, 20 uM) 
or bortezomib (BZ, 20 nM) and RNAs were isolated at the time point to perform qRT-
PCR to detect Zta, Bmrf1 and gp350 transcript levels.   
TM CLF BZ TM CLF BZ TM CLF BZ 














Figure 1-3. Clofoctol induces EBV lytic replication in BX1-Akata cells 
A. BX1-Akata cells were treated with indicated doses of clofoctol. 24 hours later, DNA 
was isolated and q-PCR was performed with EBV BamW primers 
B. BX1-Akata cells were treated with 20 uM clofoctol or anti-IgG for control. 
Fluorescence microscopy was used to determine the number of cells expressing GFP 24 
hours after the treatment.  
(A) 










Figure 1-4. Clofoctol induces Zta, but not gp350 protein expression  
Expression of Zta and gp350 proteins were measured by immunofluorescence 24 hours 






















Figure 1-5. Clofoctol activates lytic viral infection in carcinoma cells 
SNU-719 and C666 cells were treated with indicated doses of clofoctol for 24 hours. 
DNA was isolated for EBV DNA quantification by q-PCR (A) and RNA was also isolated 


















Figure 1-6. Clofoctol induces EBV lytic activation in EBV-immortalized 
lymphoblastoid cells 
A.  LCLs were treated with tunicamycin (2 μg/mL), clofoctol (20 uM) or bortezomib (20 
nM) and RNA was isolated at the time point to perform qRT-PCR to detect Zta, Bmrf1 
and gp350 transcript levels.  
B. LCLs were treated clofoctol 20 uM for 24 hours. Expression of Zta protein was 
measured by immunofluorescence and the number of cy3-Zta expressing cells were 
counted in triplicate and compared to the untreated sample.  
TM CLF BZ TM CLF BZ TM CLF BZ 
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Figure 1-7. Clofoctol inhibits virion production 
A. Raji cell infection assay was performed to determine infectious viral titers according 
to the indicated schedule. 
B and C.  Raji cells were infected with the cell-free BX1 virus supernatants of each drug 
treatment and GFP (+) Raji cells were imaged (B) and counted (C). 
D.  BX1-Akata cells were treated with anti-immunoglobulin G (10 μg/ml), TPA (20 
ng/ml) or clofoctol (20 uM) for 24 hours and isolated RNAs were used for quantification 




EBV lytic induction by bortezomib has been well characterized and here we 
confirmed the earlier report of bortezomib inducing EBV lytic gene expression in Burkitt 
cell lines. Many reports also showed that bortezomib produced its clinical activity in 
various types of gammaherpesvirus associated cancers [57, 75-77]. Our results suggest 
that clofoctol acts very similarly to bortezomib in that EBV lytic gene expression was 
similarly increased in BX1-Akata cells, although the effect was more rapid than that of 
bortezomib.  It was previously reported that bortezomib has cytotoxic effects against 
LCL without any effect on Zta induction [78]. Here we confirmed that bortezomib 
treatment of LCL does not drive any EBV lytic gene expression. However, clofoctol 
works as a potent lytic activator in LCL, as evidenced by increased RNA expression of 
Zta, Bmrf1, and gp350, and enhanced Zta protein expression. Clofoctol was also active in 
naturally infected EBV-epithelial cancer cell lines, SNU719 and C666, as viral DNA 
copy number increased in a dose-dependent manner.  
Interestingly, although all EBV lytic gene RNA expression as well as the IE Zta 
protein expression was increased by clofoctol treatment, late viral gp350 protein 
expression did not increase, nor did infectious virion production. As viral glycoproteins 
are essential for infectious virus production as well as the viral entry into cells [79], the 
repressed late viral protein expression presumably inhibited virion production. Previously, 
UPR-mediated inhibition of infectious virion production was studied with HCMV [80]. 
The report showed that the activation of the UPR by thapsigargin and clotrimazole 
significantly inhibits infectious virion production, which was attributed to the retarded 
accumulation of late gene products and the drug-induced disruption of virion maturation 
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by depleted ER calcium. A similar finding was reported with HSV, which demonstrated 
that an HIV protease inhibitor, Nelfinavir, inhibited HSV-1 viral replication by affecting 
viral glycoprotein maturation [81]. Recently, investigators discovered that several other 
drugs such as spironolactone, a mineralocorticoid receptor antagonist, and chloroquine, 
an antimalarial drug, inhibit EBV virion production without affecting lytic viral DNA 
replication [82, 83].  
Similar to clofoctol in this report, other EBV lytic inducers that work through the 
UPR, such as bortezomib and nelfinavir, do not lead to infectious virion production 
(unpublished data), which indicates a common feature of the UPR-mediated lytic 
mechanism.  As clofoctol has been used as a drug in the clinic for a decade with tolerable 
side effects, clinical trials could be performed to confirm the anticipated clinical benefit 
of the treatment of gammaherpesvirus-associated cancers and further studies to elucidate 






CHAPTER 2:  THE EFFECTS OF CLOFOCTOL ON THE UNFOLDED 
PROTEIN RESEPONSE 
SUMMARY  
As clofoctol was shown to activate the unfolded protein response (UPR) in a 
prostate cancer cell line (PC3) [64], we investigated the effects of clofoctol on the UPR in 
BX1-Akata Burkitt lymphoma cells and LCL. There are three branches in the UPR which 
are activated by each of the ER transmembrane proteins - PERK, IRE1 and ATF6 [84].  
One branch of the UPR involves PERK, which phosphorylates eIF2α leading to a 
rapid attenuation of protein synthesis but facilitating translation of the transcription factor 
ATF4 and certain other RNAs. ATF4 upregulates the expression of proteins that diminish 
ER stress, including CHOP. We found that clofoctol increased the level of 
phosphorylated eIF2α, up-regulated ATF4 and CHOP.  
A second branch of the UPR involves processing of the transcription factor XBP1 
so as to regulate expression of ER stress response genes. Activation of the UPR leads to 
splicing of XBP1 mRNA. Thus an increase in spliced XBP1 RNA (XBP1s) is indicative 
of ER stress. Using reverse transcriptase-PCR, we observed that clofoctol led to increased 
XBP1s.  
The third branch of UPR involves the activation of ATF6 by proteases leading to 
translocation of the N-terminal fragment into the nucleus with activation of target genes 




Here, we show that all branches of UPR were activated by clofoctol in BX1-
Akata cells and the effect was similar to that seen with other UPR inducers, such as 
tunicamycin and bortezomib. Clofoctol also induces all three branches of UPR in LCL, 




The switch from latent infection to lytic infection depends on the level of Zta 
(BZLF1) expression. Therefore, the molecular basis of transcription on Z promoter has 
been widely investigated by using various types of chemical or biological inducers. In 
some B cell derived EBV (+) cell lines, mimicking the B cell receptor signaling by cross-
linking with anti-immunoglobulin treatment is a potent activator of EBV and this finding 
prompted wide investigations into the regulation of the Z promotor by cellular signaling 
pathways  [85].  
Another cellular stimulus that induces viral reactivation is endoplasmic reticulum 
(ER) stress [56]. ER stress can be triggered by accumulation of misfolded proteins within 
the ER, which leads to the unfolded protein response (UPR) [60]. The UPR is a cellular 
compensatory mechanism in the ER, which plays an important role in restoring protein 
load and folding capacity [84]. It starts from three ER transmembrane sensors: Protein 
kinase RNA (PKR) - like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and 
activating transcription factor 6 (ATF6) [86] and each activates three downstream UPR 
pathways to inhibit global protein translation and activate their target genes, which help 
with proper protein folding [87]. The first branch is mediated by phosphorylation of a 
subunit of eukaryotic initiation factor 2 α (eIF2α) by oligomerized double-stranded RNA-
activated PK-like ER kinase (PERK), which preferentially translates activating 
transcription factor 4 (ATF4) to drive the expression of its target genes such as C/EBP 
homologues protein (CHOP).  The next branch of UPR starts from oligomerized inositol 
requiring enzyme 1 (IRE1) in the ER lumen, which catalyzes splicing of X-box binding 
protein 1 (XBP1) mRNA, generating a spliced isoform of XBP-1 mRNA (XBP1s).  
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Lastly, the activating transcription factor 6 (ATF6) pathway is activated by cleavage of 
the N-terminal fragment of ATF6, which translocates into the nucleus and activates its 
target genes, such as Binding immunoglobulin protein (Bip) [88]. 
As clofoctol was shown to upregulate the UPR in a prostate cancer cell line (PC3) 
[64], we investigated the effect of clofoctol on the UPR in BX1-Akata Burkitt lymphoma 
cells as well as in LCL and compared with other well-studied UPR inducers such as 
tunicamycin and bortezomib. Tunicamycin, which inhibits the N-linked glycosylation 
required for proper protein folding, is widely used as an UPR inducer [89]. Bortezomib 
inhibits the 26S proteasome and the effect on the UPR was well studied in multiple 
myeloma cells and lymphoma cells [60, 90]. Activated UPR by bortezomib was shown to 
increase CCAAT/Enhancer Binding Protein (CEBP)/beta transcription, which facilitates 




MATERIALS AND METHODS 
 Cell Culture. BX1-Akata is an engineered derivative Akata line which carries a 
recombinant EBV that constitutively expresses a green fluorescent protein (GFP) and 
LCL is an EBV-immortalized lymphoblastoid cell line. All cell lines were cultured in 
RPMI 1640, 2 mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL streptomycin and 
10% v/v fetal bovine serum (FBS). 500 μg/mL G418 (geneticin; Life Science 
Technologies) was added to the culture medium for the BX1-Akata cell line.    
 Reagents. Clofoctol was a gift from J. Liu (Johns Hopkins University School of 
Medicine) and purchased from Sigma-Aldrich. Bortezomib (20 nM) was from 
Millennium Pharmaceuticals. 
 qRT-PCR. RNA was extracted using an RNeasy Mini Kit (QIAGEN) and reverse-
transcribed into cDNA by using iScript reverse synthase kit (Bio-Rad). Reverse 
transcription was performed using a CFX96 real time thermocycler (Bio-Rad). SsoFast 
Evagreen Supermix (Bio-Rad) with 500 nM primers and cDNA corresponding to 25 ng 
of the RNA was used for each reaction.  cDNA was amplified at 95°C for 30 seconds for 
1 cycle and 95°C for 5 seconds and 60°C for 10 seconds, for total 40 cycles in a CFX96 
real time thermocycler. GAPDH primers were used as a control for normalization. 
GAPDH primers used were Forward (5’-TCTTTTGCGTCGCCAGCCGA-3’) and 
GAPDH Reverse (5’-AGTTAAAAGCAGCCCTGGTGACCA-3’). XBP1s primers used 
were Forward (5’- TGCTGAGTCCGCAGCAGGTG-3’) and XBP1s Reverse (5’-
GCTGGCAGGCTCTGGGGAAG-3’). CHOP10 primers used were Forward (5’-
AAGATGAGCGGGTGGCAGCG-3’) and CHOP10 Reverse (5’-
ACCTGCTTTCAGGTGTGGTGATG-3’). Bip/GRP78 primers used were Forward (5’-
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GTTCTTGCCGTTCAAGGTGG-3’) and Bip/GRP78 Reverse (5’-
TGGTACAGTAACAACTGCATG-3’). Trib(3) Forward (5’-
CGTGATCTCAAGCTGTGTCG-3’) and Trib(3) Reverse (5’-
AGCTTCTTCCTCTCACGGTC-3’). 
 Immunoblots.  For protein extractions, 1.5 x 107 cells were washed in PBS and 
the pellets were resuspended in a buffer containing 10 mM HEPES (pH 7.9), 10 mM 
KCl, 100 μM EDTA and 1X protease/phosphatase inhibitor cocktail (Cell Signaling 
Technologies). After 15 minutes incubation in ice, 0.6% NP-40 was added and vortexed 
for cell lysis. The cytosolic proteins were separated by centrifugation at 10,000 rpm for 
30 seconds and collected by retaining the supernatant and the pellet with the nuclear 
proteins was resuspended in a buffer containing 20 mM HEPES (pH 7.9), 400 mM NaCl, 
1 mM EDTA and 1X protease/phosphatase inhibitor cocktail.  After 15 minutes of 
rotation at 4°C, the nuclear proteins were isolated in the supernatant by centrifugation at 
13,000 rpm at 4°C for 5 minutes. SDS-PAGE and Western blotting were performed with 
equal amounts of proteins per sample and ECL chemiluminescent detection reagents (GE 
Healthcare) were used for in conjunction with autoradiography film (Denville Scientific) 
detection. Antibodies against p-eIF2α and anti-eIF2α were from Abcam, anti-ATF4 and 
anti-C/EBPβ were from Santa Cruz Biotechnology, anti- β actin from Sigma-Aldrich, 






As a previous report showed that clofoctol activates the unfolded protein response 
(UPR) in prostate cancer cell lines, we were interested in knowing whether clofoctol 
would have the same effects on EBV (+) lymphoma cells. As shown in Figure 2-1, the 
UPR consists of three branches. First, the PERK branch starts from activated PERK 
which phosphorylates eIF2α, resulting in increased ATF4 translation. ATF4 upregulates 
transcription of a variety of target genes including CHOP. We performed immunoblots to 
measure the level of phosphorylated eIF2α and ATF4, and qRT-PCR to measure CHOP 
RNA expression after clofoctol treatment of BX1-Akata cells. We found that clofoctol 
increased p-eIF2α and ATF4 protein as well as CHOP RNA (Fig. 2-2). The second 
branch of the UPR starts from the cleavage of ATF6. The N-terminal fragment of ATF6 
works as a transcription factor for turning on the target’s gene expression, such as Bip. 
Activation of the ATF6 branch by clofoctol was confirmed by immunoblot and qRT-
PCR. In the last branch of the UPR, activated IRE1 mediates the splicing of XBP1. We 
found that clofoctol increased the level of spliced isoform of XBP1 as seen in both RNA 
and protein level (Fig. 2-2).  These data suggest all three branches of UPR were activated 
by clofoctol in BX1-Akata cells. 
To further investigate the effects of clofoctol on the UPR in LCL, we performed 
qRT-PCR to measure the RNA levels of two ATF4 target genes (CHOP and Trib), an 
ATF6 target gene (Bip) and XBP1s. We found that all three branches were activated by 
clofoctol in LCLs, just as in BX1-Akata cells. Conversely, bortezomib does not activate 
any of the UPR branches in LCLs (Fig. 2-3). This result suggests that the inability of 
bortezomib to induce viral activation in LCL may be due to the inactivation of UPR. 
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C/EBPβ is one of major transcription factors that can directly bind and contribute 
to EBV Zta promoter expression, and we previously reported that Zta promoter induction 
by bortezomib is mediated by increased C/EBPβ expressions [60]. We therefore 
examined C/EBPβ levels in various types of EBV (+) cells after clofoctol treatment. As 
shown in Figure 2-4, C/EBPβ transcript level was increased in various EBV-positive cell 
lines, including EBV (+) epithelial cancer cell lines and lymphoma cell lines. The same 


























eIF2α ATF4 ↑ 
Bip S1P S2 ATF6(N) 
CHOP 
XBP1 XBP1s splicing 





Figure 2-2. Clofoctol activates the UPR in BX1-Akata cells 
BX1-Akata cells were treated with 20 uM clofoctol, proteins were extracted at the 
indicated time points and immunoblots were performed with antibody against eIF2α, p-
eIF2α, ATF4, XBP1s, ATF6 and actin. RNAs were isolated at the indicated time points 






















Figure 2-3. Clofoctol activates the UPR in LCL, but bortezomib does not 
LCL cells were treated with 20 uM clofoctol or 20 nM bortezomib, RNAs were isolated 
at the indicated time points and reverse-transcribed cDNA were used for qPCR with Trib, 

























Figure 2-4. Clofoctol increases C/EBPβ expression 
LCL, BX1-Akata, Akata EBV (+), SNU719 and C666 cells were treated with 20 uM 
clofoctol, RNAs were isolated 24 hours later and qRT-PCR was performed to detect 
C/EBPβ transcript level (A). Protein was extracted at the indicated time points from LCL 











There are several mechanisms to pharmacologically induce the UPR. 
Thapsigargin and clotrimazole are two drugs shown to activate the UPR by the disruption 
of calcium homeostasis in the ER, tunicamycin works through the inhibition of N-linked 
glycosylation of proteins and bortezomib inhibits the 26S proteasome, thus accumulated 
mis/unfolded proteins trigger ER stress and the UPR [90, 91]. The molecular mechanism 
underlying the induction of UPR by clofoctol is unclear. When comparing clofoctol’s 
effect on the UPR with bortezomib in BX1-Akata cells, UPR target gene expression was 
similarly increased, suggesting their shared pathway events.  
However, the level of lytic induction depends on cellular background, and more 
specifically, the patient sources where the cell line derived from determines the cellular 
response [72]. For example, TPA, the most widely used agent in labs for EBV lytic 
induction in majority of EBV (+) cell lines, does not work in LCL. Even within the same 
type of cell lines, the same lytic inducer treatment brings different cellular outcomes. For 
example, LCLs derived from different patients show different epigenetic patterns and 
different levels of EBV copy number per cell, resulting in differential responses to lytic 
inducers. This was evidenced by the report showing thapsigargin-induced ER stress is 
sufficient to trigger lytic replication including viral gp350 protein expression and virion 
release, but this effect was only observed in high-copy (>400 copies/cell) LCLs, not in 
low-copy (<50 copies) LCLs [56]. It was also reported that LCL are relatively resistant to 
the UPR, which was attributed to the high EBNA3C expressions [92]. Here, we also 
confirmed that bortezomib, an UPR inducer well-characterized in various cell lines, did 
not trigger the UPR in LCL. This could explain the inability of bortezomib to induce 
42 
 
EBV lytic replication in this type of cell line. Interestingly, the UPR in LCL was 
activated by clofoctol treatment. This suggests that although clofoctol and bortezomib 
might have shared pathways, the two drugs work through their distinct mechanisms and 




CHAPTER 3: THE PERK PATHWAY AND EBV LYTIC ACTIVATION 
SUMMARY 
It is well known that the unfolded protein response induces EBV lytic activation 
[69], and this was further confirmed by several studies showing that chemical agents 
which induce the UPR can activate EBV lytic infection [60]. Previous investigators 
showed that upregulated C/EBPβ and XBP1s by the UPR mediates Z promoter 
expression [37, 60]. However, the exact mechanism of EBV reactivation by the UPR is 
not clear.  
Among three branches of the UPR, the PERK pathway plays as an important 
regulator of global protein synthesis and cellular fates in response to stress stimuli. PERK 
leads to eIF2α phosphorylation, which in turn inhibits most translation, but allows some 
RNAs, including ATF4, to be translated. By using the PERK inhibitor and shRNA 
knockdown for PERK, we investigated the effect of PERK activity on EBV lytic gene 
expression induced by clofoctol. We found that knocked-down or inhibited PERK leads 
to reduced Zta expression. This suggests that Zta protein is being made with PERK 
activation and eIF2α phosphorylation, indicating that Zta translation overcomes the block 
introduced with eIF2α phosphorylation. In contrast, viral late gene gp350 which was not 
induced by clofoctol alone, was induced with clofoctol in combination with the PERK 





ER transmembrane receptor PERK is bound to the BiP chaperone protein and 
exists in an inactive state under normal physiological conditions [93]. Once PERK senses 
the accumulated misfolded or unfolded proteins in the ER, it dissociates from the BiP, 
oligomerizes, autophosphorylates and enters an active state [94]. Activated PERK 
phosphorylates α subunits of eIF2. eIF2 is composed of three subunits - α, β and γ, and 
strictly controls translation initiation in eukaryotic cells [95]. First, it binds to guanosine 
triphosphate (GTP) and initiator-methionyl-tRNA ((Met)-tRNAi) and forms a ternary 
complex. Then, this complex forms a preinitiation complex 43S with the smaller 
ribosomal subunit 40S and eukaryotic initiation factors, eIF1, eIF1A and eIF3.  A 
heterotetramer eukaryotic initiation factor 4F (eIF4F) brings mRNA into the preinitiation 
complex 43S, thus enabling the proper AUG initiation codon pairing. The resulting 
complex is called the 48S preinitiation factor and this process requires hydrolysis of GTP 
from eIF2α, which is facilitated by the GTPase-activating protein eIF5. Subsequently, the 
eIF2-GDP complex and all the other eukaryotic initiation factors are released [96] and the 
60S subunit of the ribosome binds to the 48S pre-initiation complex to complete the 80S 
initiation complex formation [97].  In order to generate a new ternary complex, eIF2β 
needs to replace the GDP to GTP [98] and this process is tightly controlled by the 
phosphorylation of eIF2α [99].  Under ER stress conditions, activated PERK 
phosphorylates eIF2α at serine 51 [100] and this stops the 5’cap-dependent global protein 
translation and allows preferential translation of selected mRNAs such as ATF4, CHOP, 
and GADD34 [101-103] that have a short upstream open reading frame (uORF) in their 5’ 
untranslated region (5’UTR) [104]. It was also found that ATF4 mRNA bypasses the Cap 
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recognition and translation starts from the direct recruitment of ribosomes to internal 
ribosome entry sites (IRES) [105], suggesting that interaction of both uORF and IRES 
elements within the 5’UTR of the stress gene regulate the cap-independent translation 
initiation [106].  
ATF4 is a basic leucine zipper (bZIP) transcription factor, which belongs to the 
activating transcription factor/cyclic AMP response element binding protein (ATF/CREB) 
family [107]. Under stress conditions, preferentially translated ATF4 drives 
transcriptional upregulation of stress-responsive genes involved in cellular amino acid 
metabolic processes, mRNA translation, and the unfolded protein response (UPR), such 
as CHOP and Trib3 [108]. Overall, the regulation of global protein synthesis is the major 
result of eIF2α phosphorylation and ATF4, which ultimately determines the cellular 
outcome [109]. 
As dysregulation of protein synthesis brings various types of pathologic 
consequences such as diabetes, cancer and neurodegenerative disease, strategies aiming 
to pharmacologically modulate this pathway have been well developed [110, 111]. For 
example, GSK2606414 was developed to prevent the PERK autophosphorylation, thus 
trapping the PERK in an inactive state [112]. Another small-molecule inhibitor, which 
works downstream of eIF2α phosphorylation, is called integrated stress response inhibitor 
(ISRIB). It has been shown to attenuate ATF4 synthesis and restore the global 
translational capacity [113]. 
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As the PERK-ATF4 pathway plays as a major regulatory role in protein synthesis 
and its activation by clofoctol was confirmed, we sought to investigate the effect of the 




MATERIALS AND METHODS 
 Cell Culture.  BX1-Akata is an engineered derivative Akata line which carries a 
recombinant EBV that constitutively expresses a green fluorescent protein (GFP) and was 
cultured in RPMI 1640, 2 mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL 
streptomycin, 10% v/v fetal bovine serum (FBS) and 500 μg/mL G418 (geneticin; Life 
Science Technologies). 
 Reagents.  Clofoctol was a gift from J. Liu (Johns Hopkins University School of 
Medicine) and purchased from Sigma-Aldrich. PERK inhibitor (GSK2606414) and 
ISRIB were obtained from MilliporeSigma.  
 qRT-PCR.  RNA was extracted using an RNeasy Mini Kit (QIAGEN) and 
reverse-transcribed into cDNA by using iScript reverse synthase kit (Bio-Rad). Reverse 
transcription was performed using a CFX96 real time thermocycler (Bio-Rad). SsoFast 
Evagreen Supermix (Bio-Rad) with 500 nM primers and cDNA corresponding to 25 ng 
of the RNA was used for each reaction.  cDNA was amplified at 95°C for 30 seconds for 
1 cycle and 95°C for 5 seconds and 60°C for 10 seconds, for a total of 40 cycles. GAPDH 
primers were used as a control for normalization. GAPDH primers used were Forward 
(5’-TCTTTTGCGTCGCCAGCCGA-3’) and GAPDH Reverse (5’-
AGTTAAAAGCAGCCCTGGTGACCA-3’). EBV Zta primers used were Forward (5’-
ACATCTGCTTCAACAGGAGG-3’) and EBV Zta Reverse (5’-
AGCAGACATTGGTGTTCCAC-3’). Trib primers used were Forward (5’-
CGTGATCTCAAGCTGTGTCG-3’) and Trib Reverse (5’-




 Immunofluorescence. For staining cells with Cy3, 1.5 x 105 cells were spun onto 
microscope slides by using a Cytospin centrifuge, fixed/permeabilized with ice-cold 
methanol for 15 minutes, blocked in PBS with 5% Bovine serum albumin (BSA) for 30 
minutes, incubated with anti-EBV Zta or gp350 mouse antibody at 1:50 for 1 hour, 
washed three times for ten minutes each with 5% BSA, 0.1% Tween-20 in PBS and Cy3 
goat anti-mouse antibody (Jackson Immunoresearch) was applied to the cells for 1 hour 
at room temperature. After 3 final washes, the cells were stained with Vectashield 
mounting media with DAPI (Vector Laboratories). The ZOE Fluorescent cell imager 
(Bio-Rad) was used for cell fluorescence detection. 
 shRNA knockdown.  shRNA Plasmids consisting of a pool of three to five 
lentiviral vector plasmids designed to knockdown PERK gene expression were purchased 
from Santa Cruz biotechnology. Transduction of the lentiviral particles was performed 
according to the manufacturer’s protocol and stable cell lines expressing the shRNA were 




ER stress triggers PERK dependent phosphorylation of eukaryotic translation 
initiation factor 2 alpha (eIF2α) and translation of ATF4 is selectively upregulated by the 
phosphorylated eIF2α. To investigate whether PERK mediates the effects of clofoctol, we 
tried to modulate the activity of PERK by either using a PERK inhibitor (GSK2606414) 
or short hairpin RNA (shRNA) lentiviral vector plasmids to knockdown PERK gene 
expression. We also used another small molecule inhibitor of the pathway called 
integrated stress response inhibitor (ISRIB), which reverses the phosphorylated state of 
eIF2α [113]. RNA level of ATF4 target gene Trib was measured as an indicator of the 
PERK activity (Fig. 3-1). 
As shown in Figure 3-2, clofoctol treatment alone increased Trib and Zta RNA 
expression as well as GFP expression in BX1-Akata cells and PERK inhibitor treatment 
resulted in decreases of the expressions induced by clofoctol. To further validate the 
impact of blocking PERK, BX1-Akata cells were transfected with shRNA targeting 
PERK and the puromycin selected cells were treated with or without clofoctol. We found 
clofoctol mediated increased Zta RNA and GFP expressions were inhibited in the 
presence of shPERK (Fig. 3-3). Blocking the downstream of eIF2α phosphorylation by 
ISRIB also reduced the increased level of Trib, Zta RNA and GFP expression by 
clofoctol in BX1-Akata cells (Fig. 3-4). This result suggests that the PERK pathway 
mediates EBV lytic activation by clofoctol. Activated PERK leads to eIF2α 
phosphorylation which in turn inhibits most translation, but allows some RNAs including 
ATF4 to be translated. In our results, Zta protein synthesis was enhanced with PERK 
activation by clofoctol treatment, suggesting Zta translation overcomes the eIF2α 
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phosphorylation mediated translational block. Furthermore, we found the PERK pathway 
differentially regulates viral lytic gene expression at the protein level. Clofoctol treatment 
alone triggers expression of the immediate early protein Zta. However, Zta expression 
was reduced by treatment with a PERK inhibitor. In contrast, expression of the viral late 
lytic protein gp350 was not increased by clofoctol alone but was increased by the 
combination of clofoctol and PERK inhibitor (Fig. 3-5).  This result suggests that 
clofoctol activates other branches of the UPR and that these also are important in driving 













Figure 3-1. Modulation of PERK activity 
Treatment of GSK2606414 for inhibiting PERK activity or short hairpin RNA (shRNA) 
lentiviral vector plasmids to knockdown PERK gene expression. ISRIB targets 
downstream events of eIF2α phosphorylation.   













Figure 3-2. An inhibitor of PERK reduces EBV Zta activation by clofoctol 
BX1-Akata cells were pre-treated with indicated doses of PERK inhibitor (uM) for 30 
minutes, followed by clofoctol or no treatment. 24 hours later, the GFP (+) cells were 
detected by fluorescence microscopy and isolated RNA was used for quantification of 
Trib and Zta transcript level. 





Figure 3-3. shRNA knockdown of PERK reduces EBV Zta activation by clofoctol 
BX1-Akata cells were transfected with shRNA lentiviral vector plasmids designed to 
knockdown PERK gene expression. After the transfection, cells with shRNAs were 
selected by puromycin. qRT-PCR was performed to confirm the PERK knockdown and 
the Zta RNA quantification after 24 hours of clofoctol treatment. Fluorescence 






Figure 3-4. ISR inhibitor (ISRIB) reduces EBV Zta activation by clofoctol 
BX1-Akata cells were pretreated with ISRIB for 30 minutes and followed by either 
clofoctol or no treatment. RNA was isolated for Zta and Trib RNA quantification 24 
hours after the treatment. Fluorescence microscopy was used for detecting the GFP (+) 
cells 24 hours after the treatment. 



















Figure 3-5. Differential effect of PERK inhibition on viral protein expressions 
BX1-Akata cells were pretreated with PERK inhibitor (PERKi) 7.5 uM for 30 minutes 
and followed by clofoctol (20 uM) treatment. 24 hours later, immunofluorescence was 
performed to detect Zta and gp350 protein expressions. RNA was isolated to measure 




















Activated PERK prevents ternary complex formation by eIF2α phosphorylation in 
order to attenuate global protein translation. Our results show that clofoctol treatment 
activates the PERK pathway, as evidenced by the increase of eIF2α phosphorylation, 
ATF4 and CHOP expression and this accounts for the inhibited viral gp350 protein 
expression despite the high mRNA levels seen. However, we saw increased Zta protein 
expression with clofoctol treatment, indicating that Zta translation overcomes PERK-
mediated translation inhibition. We also found that inhibition of PERK resulted in 
reduced expression of Zta by clofoctol treatment, suggesting that the expression is at least 
partially mediated by the PERK pathway.   
When cells are exposed to environmental stress, it is critical to regulate the rate of 
translation for adaptation and cell fate decision. There are two broad categories of protein 
regulation. One is blocking the global protein translation and the other is selective 
translation of proteins which are essential for the cellular stress response [114]. Under 
stress conditions, mTOR or eIF2α kinases inhibit the translation initiation by affecting the 
eIF4E or eIF2 ternary complex formation in the cap-dependent mechanism.  Whereas, the 
selective translation of protein is mediated by sequence signatures present in the 5’ 
untranslated regions (UTR) in the stress genes which enable the translation initiation 
without the cap recognition from the initiation factors. Several functional elements have 
been found, and internal ribosome entry site (IRES) and upstream open reading frame 
(uORF) are the examples. IRES allows direct recruitment of 40S ribosome to the site 
which is called internal initiation and many reports verified that the selective IRES-
mediated protein translation plays important role for determining cellular fate in various 
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types of pathogenesis [115, 116]. IRES dependent translation was first identified in 
poliovirus [117] and has since been characterized in other viruses including KSHV [118] 
and EBV [119].  The presence of IRES within the 5’UTR of the EBNA1 promotes cap-
independent translation and enhances EBNA1 protein expression. uORF is another 
transcript sequences found in 5’UTR of stress genes such as ATF4. Under normal 
conditions, ribosomes engage only in the uORF, but under stress conditions, ribosomes 
pass through the uORF and start the translation of the main coding ORF. Interactions of 
both uORF and IRES elements within the 5’UTR of the stress gene regulate the 
translation initiation in cap-independent manner [106]. Additionally, another form of 
eIF2α-independent translation was revealed, which is mediated by eIF5B instead of eIF2 
for translation initiation [120]. This process is called eIF5B-dependent translation 
initiation and the increased level of eIF5B accompanied by the high level of eIF2α 
phosphorylation is demonstrated in various types of stress conditions [121, 122].  
Our findings suggest the possibility that translation initiation of Zta is regulated in 
a non-classical way of cap-independent or eIF2α-independent manner and further 
experiments are required to elucidate the precise mechanism of Zta overcoming the 
translation block. 
Another interesting finding we observed with the PERK inhibition assay was the 
enhanced protein expression of gp350. Clofoctol treatment alone did not elicit gp350 
protein expression. Presumably, it was inhibited by the PERK-mediated translation block 
as it appeared with the PERK inhibitor. The appearance of gp350 with clofoctol and 
PERK inhibitor treatment suggests that the other UPR pathways are contributing to viral 
lytic protein expression. Additionally, the level of Zta protein expression with clofoctol 
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and PERK inhibitor treatment was slightly higher than the basal level, also suggesting 
stimulation from the other UPR pathways.  One such pathway is the IRE1-XBP1 pathway. 
Under ER stress, the UPR sensor IRE1 homodimerizes, autophosphorylates and catalyzes 
the splicing of XBP1 mRNA, resulting in a spliced isoform of XBP1 (XBP1s). After 
being translated, it regulates the transcription of various cellular genes as a transcription 
factor and its expression is required for cellular secretory process, increase of protein 
synthesis as well as terminal B cell differentiation [123, 124]. Additionally, it was shown 
to directly bind to the Z promoter and upregulates Z promoter activation [36, 37]. It is 
apparent that activated XBP1 as a result of clofoctol treatment might also contribute to 
viral lytic gene expression.  
The products of uORF translation of the stress response genes were predicted to 
be MHC I peptides active in adaptive immunity [125]. As combinational treatment of 
clofoctol and PERK inhibitor drive immediate early and late viral protein expression and 
normal host T cell response effectively reacts to viral lytic antigens, our results suggest 
possible therapeutic implications that the combinational strategy might increase the 




CHAPTER 4: THE INTEGRATED STRESS RESPONSE AND EBV LYTIC 
ACTIVATION 
SUMMARY 
A range of physiological stress conditions were found to induce the integrated 
stress response (ISR), such as hypoxia, amino acid deprivation and viral infection. There 
are four different kinases that phosphorylated eIF2α in response to their specific stress 
stimuli: PERK, HRI, PKR and GCN2. A variety of chemical reagents were discovered to 
specifically enhance kinase activity. Clofoctol-induced EBV lytic activation mediated by 
PERK raised the possibility that pharmacological activation of other eIF2α kinases might 
induce viral activation as well. To further investigate whether activated ISR signaling by 
different stimuli promotes Zta expression, BX1-Akata cells were treated with four 
different chemical compounds shown to trigger each kinase’s activity. CCT020312 was 
used for PERK activation, arsenite was used for HRI activation, poly(I:C) was 
nucleofected into cells for PKR activation and halofuginone was treated for GCN2 
activation. Lastly, nelfinavir was treated for enhancing the eIF2α phosphorylation by 
blocking the dephosphorylation process. The treatments all induced EBV Zta RNA 
expression and increased viral replication was indirectly indicated by enhanced GFP 




PERK phosphorylation of eIF2α has long been recognized as a branch of the UPR, 
but other kinases associated with distinct stress pathways also lead to phosphorylation of 
eIF2α. The integrated stress response (ISR) refers to the convergence of these stress 
signaling pathways on phosphorylation of eIF2α [126]. In addition to PERK, the other 
kinases that phosphorylate eIF2α are double-stranded RNA-dependent protein kinase 
(PKR), heme-regulated eIF2α kinase (HRI), and general control non-derepressible 2 
kinase (GCN2). These 4 eIF2α kinases responses to their distinct stress stimuli 
phosphorylate the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α) in 
order to turn off global protein synthesis and selected genes, which do not require Cap 
recognition by the eIF4F complex, are therefore being preferentially translated [126]. 
First, PERK is located in the endoplasmic reticulum (ER) membrane and its 
activation is derived from ER stress, which is also a part of the unfolded protein response. 
One of the compounds that selectively activated PERK without triggering a general UPR 
was discovered and shown to promote eIF2α phosphorylation [127]. HRI in erythroid 
cells is activated by the absence of heme [128], arsenite-induced oxidative stress [129] 
and 26S proteasome inhibition [130]. A chemical compound called BTdCPU has been 
found to specifically target HRI activation [131]. GCN2 is activated in response to amino 
acid deprivation [132], and halofuginone, a cancer drug in clinical trials, was shown to 
activate GCN2 and phosphorylates eIF2α [133, 134]. PKR is activated mainly by double-
stranded RNA (dsRNA) during viral infection [135]. It was also shown that nucleofection, 
even in the absence of the delivered nucleic acid, leads to transient eIF2α 
phosphorylation by GCN2 and PERK [136]. 
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The downstream point of regulation of the ISR signal is the dephosphorylation of 
eIF2α to restore the protein synthesis [137]. Reversing the phosphorylation of eIF2α is 
mediated by protein phosphatase 1 (PP1) and there are two cellular cofactors of PP1: 
GADD34 (PPP1R15A) and CReP (Constitutive Repressor of eIF2α Phosphorylation, 
PPP1R15B). GADD34 terminates the response by specifically directing PP1 to 
dephosphorylate eIF2α [137], and CReP maintains eIF2α phosphorylation in a low level 
[138]. Recently, it was reported that IRE1 branch of the UPR increases eIF2α 
phosphorylation by degrading the mRNA of CReP, indicating that CReP expression is 
controlled in an IRE1-dependent manner in order to efficiently regulate protein synthesis 
[139]. Several clinically used drugs were shown to enhance the ISR by regulating the 
activity of GADD34 or CReP. For example, the HIV protease inhibitor Nelfinavir was 
recently shown to activate the ISR by downregulating CReP level and decrease the 
dephosphorylation activity of PP1, thus enhancing eIF2α phosphorylation [140]. 
To better understand the impact of ISR on EBV lytic activation, we utilized 
pharmacological activation of ISR signaling and evaluated the effect on virus in BX1-




MATERIALS AND METHODS 
 Cell Culture. BX1-Akata is an engineered derivative Akata line which carries a 
recombinant EBV that constitutively expresses a green fluorescent protein (GFP) and was 
cultured in RPMI 1640, 2 mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL 
streptomycin, 10% v/v fetal bovine serum (FBS) and 500 μg/mL G418 (geneticin; Life 
Science Technologies). 
 Reagents. Clofoctol was purchased from Sigma-Aldrich. Nelfinavir, EIF2AK3 
activator (CCT020313), Polyinosinic:polycytidylic acid (poly (I:C)) and arsenite were 
purchased from MilliporeSigma. Halofuginone was purchased from Cayman chemical.  
 qRT-PCR. RNA was extracted from the RNeasy Mini Kit (QIAGEN) and 
reverse-transcribed into cDNA by using iScript reverse synthase kit (Bio-Rad). Reverse 
transcription was performed using a CFX96 real time thermocycler (Bio-Rad).  SsoFast 
Evagreen Supermix (Bio-Rad) with 500 nM primers and cDNA corresponding to 25 ng 
of the RNA was used for each reaction. cDNA was amplified at 95°C for 30 seconds for 
1 cycle and 95°C for 5 seconds and 60°C for 10 seconds, for a total of 40 cycles using a 
CFX96 real time thermocycler. GAPDH primers were used as a control for 
normalization. GAPDH primers used were Forward (5’-
TCTTTTGCGTCGCCAGCCGA-3’) and GAPDH Reverse (5’-
AGTTAAAAGCAGCCCTGGTGACCA-3’). EBV Zta primers used were Forward (5’-
ACATCTGCTTCAACAGGAGG-3’) and EBV Zta Reverse (5’-
AGCAGACATTGGTGTTCCAC-3’). EBV Bmrf1 primers used were Forward (5’-
CTAGCCGTCCTGTCCAAGTGC-3’) and EBV Bmrf1 Reverse (5’-
AGCCAAACGCTCCTTGCCCA-3’). EBV gp350 primers used were Forward (5’-
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GTCAGTACACCATCCAGAGCC-3’) and EBV gp350 Reverse (5’-
TTGGTAGACAGCCTTCGTATG-3’).   
 Nucleofection. Poly(I:C) nucleofection was performed by using an Amaxa 
nucleofector device according to the manufacturer’s protocol from the Amaxa Cell Line 





There are four eIF2α kinases (PERK, HRI, PKR and GCN2) which sense distinct 
environmental and physiological stresses. Phosphorylation of eIF2α triggers the 
integrated stress response (ISR). We treated BX1-Akata cells with four compounds each 
of which stimulates a different eIF2α kinase and monitored lytic activation (Fig. 4-1). 
CCT020312 was used to activate PERK, arsenite was used to activate HRI, poly(I:C) was 
nucleofected into cells to activate PKR, and halofuginone was used to activate GCN2. 24 
hours after treatment, we performed qRT-PCR to measure Zta gene expression, and GFP 
expression was detected by fluorescence microscopy. We found that treatment by all four 
eIF2α kinase stimulators led to increases in Zta RNA expression and GFP expression in 
BX1-Akata cells. 
A previous report showed that nelfinavir induces the ISR by inhibiting the 
dephosphorylation of eIF2α (Fig. 4-3) [140]. We confirmed the nelfinavir-mediated ISR 
activation which was indicated by upregulation of Trib gene expression and also found 
increased viral lytic gene expression after nelfinavir treatment.  
 Together these data show that activation of eIF2α phosphorylation by various 







Figure 4-1. Integrated stress response stimulation 
CCT020313 (7 uM), poly (I:C) (10 ug/ml), arsenite (50 uM) and halofuginone (70 nM) 













Figure 4-2. ISR stimuli activate Zta gene expression and increase GFP expression in 
BX1-Akata cells 
BX1-Akata cells were treated with clofoctol (20 uM), PERK activator (CCT020313, 7 
uM), arsenite (50 uM) and halofuginone (70 nM), and nucleofected with poly(I:C) (10 
ug/ml) for the ISR stimulation. 24 hours later, RNA was isolated for quantification of Zta 
transcript level and GFP positive cells were detected by fluorescence microscopy.  
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Figure 4-3. Nelfinavir activates the ISR and EBV lytic gene expression 
A. Nelfinavir inhibits the constitutive eIF2α dephosphorylation by downregulation of the 
phophatase cofactor CReP (Constitutive Repressor of eIF2α Phosphorylation; also known 
as PPP1R15B).   
B. BX1-Akata cells were treated with nelfinavir (20 uM) for 24 hours and isolated RNA 










Here we show several reagents that specifically activate eIF2α phosphorylation 
also induce the EBV lytic gene expression thus confirming that ISR pathways lead to 
EBV lytic activation. In combination with evidence that clofoctol leads to eIF2α 
phosphorylation, this provides evidence that clofoctol activation of EBV lytic infection 
can be accounted for, at least in part, by activation of the ISR.  
Arsenite exposure leads to the dose-dependent and tissue-dependent apoptosis and 
has been used for the treatment of certain types of cancers such as acute promyelocytic 
leukemia and multiple myeloma [141]. One of the most immediate cellular responses to 
arsenite exposure is inhibition of protein synthesis by phosphorylation of the eIF2α 
through HRI and such a drastic reduction of translation plays a cytoprotective role [129].  
Halofuginone (Tempostatin), a synthetic quinazolinone alkaloid derivative, was 
shown to have  anti-angiogenic, anti-metastatic, and anti-proliferative effects in 
preclinical studies [142] and was studied in a phase II study in patients with AIDS related 
Kaposi sarcoma (KS)(AMC 036) [143]. 
Nelfinavir is an HIV aspartyl protease inhibitor. In vitro and in vivo studies 
showed anti-cancer effects related to induction of apoptosis, ER stress and autophagy 
even in the absence of HIV infection [144]. It was recently shown that nelfinavir affects 
translation in two different ways [145]. Nelfinavir enhances the phosphorylation of eIF2α 
to inhibit the translation initiation [140] and activates eukaryotic elongation factor 2 
kinases (eEF2K) leading to the phosphorylation of the elongation factor eEF2, thereby 
blocking translation elongation [146]. It was suggested that the cytotoxic effects of 
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nelfinavir reflect alterations in translation that are similar to those resulting from 
inhibition of mTORC1 by rapamycin [146]. 
Drug repositioning is considered as a low-risk and low-cost strategy that has been 
widely used to identify new clinical opportunities for old drugs. As some of drugs we 
tested are already approved for use in humans, it would be advantageous to further 
investigate its possible implication for EBV associated cancer treatment. 
Although pharmacological agents were used in this study to elicit the ISR, various 
environmental and physiological conditions were well-known to trigger the pathway. For 
example, GCN2 becomes active in amino acid deprived condition [132]. HRI becomes 
active by heme deficiency for the production of hemoglobin and can also be activated by 
other stresses including oxidative stress, heat shock, and osmotic stress [147]. Further 
investigations may provide a broader insight to understand relevant physiologic stimuli 




In this study, we found a drug that activates EBV in diverse latently infected cell 
lines. Clofoctol has been widely used in Europe as an antibiotic and is well-tolerated. The 
effects of the drug on viral gene regulation have not been previously reported. Its effects 
on mammalian cell stress pathways was revealed following a drug screen to identify 
compounds that were toxic to prostate cancer cell lines [64]. The previous report 
suggested that clofoctol works on the unfolded protein response (UPR) and inhibits 
prostate cancer cell growth. We also confirmed the activation of the UPR pathway by 
clofoctol, which results in EBV lytic gene expression in various types of EBV-harboring 
cancer cell lines. Clofoctol treatment drives the transcription of EBV lytic genes and 
translation of immediate early lytic protein Zta, but does not induce the translation of late 
lytic proteins or production of infectious virions.  
Upon the stimulation of a stress signal, cells stop producing peptides from 
conventional translation in order to conserve resources and survive under stressful 
conditions. Stress response kinases phosphorylate eIF2α, leading to downregulation of 
eIF2-dependent translation from an AUG start codon. Under ER stress, one UPR sensor, 
PERK, becomes active and induces phosphorylation of eIF2α, thus stopping global 
translation. In this report, we found that the EBV immediate early lytic protein Zta was 
being made in the presence of phosphorylated eIF2α, indicating that the translation of Zta 
escapes the global translational inhibition.   
A recent study supported the idea of T cell recognition of the peptide translated 
from uORF after stress-induced eIF2α phosphorylation [125]. To be detected by T cells, 
the intracellular protein must be degraded, loaded onto an MHC 1 molecule and 
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presented on the cell surface. Then, the peptide can be recognized by a T cell with a T-
cell receptor specific for that antigen. This process is highly sensitive, as T cells are able 
to detect even a few copies of the peptide–MHC I complex. From our results, it is 
possible to predict that the EBV Zta protein which escaped from translational 
downregulation might ultimately be presented into the T cell recognition mechanism.  
Furthermore, our results showed that the expression of the viral late lytic protein 
gp350 appeared with co-treatment of clofoctol and a PERK inhibitor. This result suggests 
that clofoctol activates other branches of the UPR that are also driving EBV lytic gene 
expression and attenuation of the translational block by the PERK inhibitor led to gp350 
expression.  
The EBV genome encodes more than 80 open reading frames and most of them 
elicit immunologic responses. We hypothesize that combination treatment with clofoctol 
and a PERK inhibitor will drive expression of most lytic genes, enhancing functional T 
cell responses. 
Although viral activation from the UPR has been well studied, our study broadens 
insights into stress stimuli that affect viral activation. Not only ER stress, but also other 
environmental stress conditions which drive the ISR could induce viral activation, and 
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